Your browser doesn't support javascript.
loading
Skip pattern approach toward the early access of innovative anticancer drugs.
Apolone, G; Ardizzoni, A; Biondi, A; Bortolami, A; Cardone, C; Ciniselli, C M; Conte, P; Crippa, C; de Braud, F; Duca, M; Gori, S; Gritti, G; Inno, A; Luksch, R; Lussana, F; Maio, M; Pasello, G; Perrone, F; Rambaldi, A; Rossi, G; Signorelli, D; Soverini, G; Valente, M; Verderio, P; Buzzetti, G.
Affiliation
  • Apolone G; Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Ardizzoni A; Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
  • Biondi A; Department of Pediatrics, University of Milano Bicocca-Fondazione MBBM/Ospedale San Gerardo, Monza, Italy.
  • Bortolami A; Rete Oncologica Veneta, Istituto Oncologico Veneto, Padova, Italy.
  • Cardone C; Experimental Clinical Abdominal Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.
  • Ciniselli CM; Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Conte P; Istituto Oncologico Veneto, Padova, Italy.
  • Crippa C; Department of Hemathology, Spedali Civili di Brescia, Brescia, Italy.
  • de Braud F; Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Duca M; Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Gori S; Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital of Negrar, Verona, Italy.
  • Gritti G; Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Inno A; Department of Oncology, IRCCS Sacro Cuore Don Calabria Hospital of Negrar, Verona, Italy.
  • Luksch R; Department of Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Lussana F; Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Maio M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
  • Pasello G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Perrone F; Clinical Trials Unit, National Cancer Institute of Naples, Napoli, Italy.
  • Rambaldi A; Department of Oncology-Hematology, University of Milan, Milano, Italy; Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Rossi G; Deparment of Hematology ASST Spedali Civili di Brescia, Brescia, Italy.
  • Signorelli D; Department of Medical Oncology & Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Niguarda Cancer Center-Grande Ospedale Metropolitano Niguarda, Milano, Italy.
  • Soverini G; Deparment of Hematology ASST Spedali Civili di Brescia, Brescia, Italy.
  • Valente M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
  • Verderio P; Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: paolo.verderio@istitutotumori.mi.it.
  • Buzzetti G; Dephaforum, Milano, Italy.
ESMO Open ; 6(4): 100227, 2021 08.
Article in En | MEDLINE | ID: mdl-34352703

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Neoplasms / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: ESMO Open Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Neoplasms / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: ESMO Open Year: 2021 Document type: Article